Study Finds Methadone May Reduce Death Risk More Than Buprenorphine for Overdose Survivors

A retrospective cohort study published August 26, 2026, in JAMA Network Open suggests that among survivors of opioid overdose, initiating treatment with methadone may reduce the risk of death within one year compared with starting buprenorphine-naloxone. The Canadian study of nearly 6,000 patients found a modest but statistically significant mortality difference, though accompanying commentary from addiction experts urges caution in interpreting the findings.

Researchers led by Dr. Robert A. Kleinman at the Center for Addiction and Mental Health in Toronto analyzed outcomes for 5,882 individuals who experienced an opioid overdose and subsequently started either methadone or buprenorphine-naloxone treatment in Ontario between 2017 and 2023. Using a target trial emulation design with propensity score matching, the study compared one-year mortality rates between the two groups.

The Mortality Gap

Among patients who started methadone, 5.6% died within one year compared with 7.1% of those who started buprenorphine-naloxone—a relative risk reduction of approximately 22% (hazard ratio 0.78, 95% CI 0.63-0.95, P=0.01). The difference was driven primarily by opioid overdose deaths: 3.8% of methadone patients died from overdose versus 5.1% in the buprenorphine-naloxone group.

"The short treatment durations, high rates of mortality, and repeat opioid overdose among this group of individuals who started recommended treatments for opioid use disorder highlight the importance of improving treatment outcomes in this high-risk group," Kleinman and colleagues concluded.

The study also found meaningful differences in treatment retention. Median time to discontinuation was 25 days for methadone patients versus just 16 days for those on buprenorphine-naloxone. However, time to first opioid overdose did not significantly differ between the two groups.

Experts Question the Conclusion

In an accompanying commentary, Dr. Evan Wood of the University of British Columbia and Dr. Leen Naji of the University of Arizona threw cold water on the inference that methadone is "intrinsically superior" to buprenorphine-naloxone for overdose survivors.

Their skepticism rests on several methodological considerations. Per-protocol analyses—focusing only on patients who continued treatment—showed no significant mortality difference between the medications (HR 0.84, 95% CI 0.48-1.47). Additionally, patients without prior opioid agonist treatment exposure showed no mortality difference at all (HR 1.00, 95% CI 0.67-1.50).

Perhaps most tellingly, while on treatment, buprenorphine-naloxone patients actually experienced a lower risk of overdose than those taking methadone (HR 1.52 for methadone, 95% CI 1.19-1.93, P<0.001). This finding complicates the narrative of methadone's superiority.

"The most noteworthy finding of the study may not be the potential modest relative differences between medications, but rather the persistently poor outcomes observed among overdose survivors regardless of treatment choice," Wood and Naji wrote. Approximately 6% of participants died within a year, more than one-quarter experienced another overdose, and nearly 90% discontinued treatment during follow-up.

The Real Problem: Treatment Retention

The commentary authors argue that researchers and policymakers should shift focus away from debating the "relative merits" of different opioid agonist treatments and instead confront why "initiating and remaining on this treatment is so unattractive to most patients."

Both medications are highly effective when patients take them. The challenge lies not in choosing between methadone and buprenorphine but in creating treatment environments and support systems that encourage sustained engagement. Current models—particularly methadone clinics requiring daily observed dosing—impose significant structural barriers that drive discontinuation.

For patients seeking help, medication-assisted treatment programs offer various options including both methadone and buprenorphine. The study's findings do not suggest changing prescribing practices but rather reinforce the need for improved retention strategies across all medication types.

Study Context and Limitations

The Ontario study population had a mean age of 35.8 years and was 67.9% male. Notably, 56.6% of participants had received opioid agonist treatment within the previous three years, suggesting a population with significant treatment history and potentially higher baseline risk.

Generalizability may be limited by the fact that approximately 40% of eligible individuals were excluded after propensity score matching. The Canadian healthcare context—universal coverage and different methadone clinic regulations—may also limit direct applicability to the U.S. setting.

Wood and Naji noted that "confirmation in other settings may be valuable" before drawing firm conclusions about medication superiority for overdose survivors.

What This Means for Clinical Practice

The study does not provide grounds for preferentially prescribing methadone over buprenorphine-naloxone for overdose survivors. Both medications remain first-line treatments for opioid use disorder, and the choice between them should continue to be individualized based on patient preferences, access to treatment facilities, and medical considerations.

The more urgent takeaway is the alarmingly high mortality and discontinuation rates among overdose survivors regardless of medication choice. This population—already demonstrated to be at elevated risk through their overdose history—requires intensive, patient-centered interventions that go beyond medication selection to address the full spectrum of barriers to sustained recovery.

As the nation continues to grapple with the opioid crisis, studies like this serve as important reminders that while medications for opioid use disorder save lives, getting patients to take them consistently—and keeping them engaged in care—remains the central challenge facing addiction medicine.